Citeline provided feasibility data and insights to help Biorasi complete a Phase III oncology trial with 89% site validation, 8 priority countries, and a 15–20% predicted enrollment lift from a protocol optimization.

At Citeline (a Norstella company), we are a global leader in clinical trial intelligence, data, and insights for the life sciences and pharmaceutical industries. We help organizations accelerate drug development, enhance transparency, and improve clinical outcomes through real‑time, decision‑ready intelligence across the entire drug lifecycle. Our solutions provide one of the most comprehensive and continuously updated views of global clinical trials, investigators, sites, pipelines, regulatory requirements, and competitive landscapes—enhanced with AI, curated datasets, and expert analysis. This empowers pharma, biotech, and CRO partners to plan smarter, recruit faster, maintain compliance, and reduce development risk. Our core offerings include: • Clinical Trial Intelligence: Real‑time global data on trials, investigators, and sites. • Drug Development Intelligence: Pipeline insights, market assessments & competitive analysis. • Regulatory & Compliance Intelligence: Tools to support disclosure compliance, mitigate risk & streamline submission workflows. • Competitive Intelligence: Industry and therapeutic‑area insights to stay ahead of evolving markets. Powered by machine learning, real‑world data, and expert‑led research, Citeline delivers reliable, actionable intelligence used by global pharmaceutical companies, CROs, and life sciences innovators. As part of Norstella, we work together to accelerate the connection of treatments to patients around the world.